2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
12.11.14
Parent Project Muscular Dystrophy To Collaborate With Catabasis Pharmaceuticals, Inc. On CAT-1004 Development
11.24.14
Catabasis Pharmaceuticals Receives FDA Orphan Drug Designation for CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
11.18.14
Catabasis Names Angelika Fretzen, Ph.D., Vice President of Development
09.30.14
Catabasis Pharmaceuticals Management to Present at October Investor Conferences
09.29.14
Catabasis Pharmaceuticals to Present at International Congress of the World Muscle Society
08.06.14
Catabasis Pharmaceuticals to Present at Wedbush 2014 Life Sciences Management Access Conference
06.24.14
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference and New Directions in Biology and Disease of Skeletal Muscle Conference
06.11.14
Catabasis Pharmaceuticals Announces Issuance of Three New US Patents for CAT-1000 Series
05.02.14
Catabasis Demonstrates CAT-2003 Lowers Fed and Fasting Triglycerides in Studies Presented at Lipid Conferences
05.01.14
Catabasis Describes Modulation of SREBP as Mechanism for CAT-2003
04.25.14
Catabasis to Present CAT-2003 Data at Upcoming Lipid Conferences
03.31.14
Catabasis to Present CAT-2003 Data at the American College of Cardiology’s 63rd Annual Scientific Session
03.14.14
Catabasis to Present Data on CAT-1004 at the Muscular Dystrophy Association’s 2014 Clinical Conference
02.26.14
Catabasis Names Andrew Nichols, Ph.D., Vice President of Research
02.04.14
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
01.08.14
Catabasis to Present at 32nd Annual J.P. Morgan Healthcare Conference
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.